DE719145T1 - Stickstoffoxyd abgebendes präparat und verfahren zur behandlung von analen erkrankungen - Google Patents
Stickstoffoxyd abgebendes präparat und verfahren zur behandlung von analen erkrankungenInfo
- Publication number
- DE719145T1 DE719145T1 DE0719145T DE95916264T DE719145T1 DE 719145 T1 DE719145 T1 DE 719145T1 DE 0719145 T DE0719145 T DE 0719145T DE 95916264 T DE95916264 T DE 95916264T DE 719145 T1 DE719145 T1 DE 719145T1
- Authority
- DE
- Germany
- Prior art keywords
- organic
- oxide donor
- nitric oxide
- anal
- nitroglycerin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract 20
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title claims 14
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract 17
- 239000002840 nitric oxide donor Substances 0.000 claims abstract 14
- 208000016583 Anus disease Diseases 0.000 claims abstract 12
- 230000000699 topical effect Effects 0.000 claims abstract 10
- 230000003444 anaesthetic effect Effects 0.000 claims abstract 7
- 239000003246 corticosteroid Substances 0.000 claims abstract 6
- 208000009531 Fissure in Ano Diseases 0.000 claims abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 4
- 206010002153 Anal fissure Diseases 0.000 claims abstract 2
- 206010002180 Anal ulcer Diseases 0.000 claims abstract 2
- 208000005392 Spasm Diseases 0.000 claims abstract 2
- 208000014617 hemorrhoid Diseases 0.000 claims abstract 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical group [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims 12
- 239000000006 Nitroglycerin Substances 0.000 claims 12
- 229960003711 glyceryl trinitrate Drugs 0.000 claims 12
- 239000002674 ointment Substances 0.000 claims 6
- 125000001145 hydrido group Chemical group *[H] 0.000 claims 5
- 239000004215 Carbon black (E152) Substances 0.000 claims 4
- 229910002651 NO3 Inorganic materials 0.000 claims 4
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 4
- 206010036772 Proctalgia Diseases 0.000 claims 4
- 229930195733 hydrocarbon Natural products 0.000 claims 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 4
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 claims 3
- 229960005450 eritrityl tetranitrate Drugs 0.000 claims 3
- SNFOERUNNSHUGP-ZXZARUISSA-N erythrityl tetranitrate Chemical compound [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@@H](O[N+]([O-])=O)CO[N+]([O-])=O SNFOERUNNSHUGP-ZXZARUISSA-N 0.000 claims 3
- 125000001477 organic nitrogen group Chemical group 0.000 claims 3
- 239000000829 suppository Substances 0.000 claims 3
- GFVHBTOOPNJKLV-UHFFFAOYSA-N 1,2-dinitroglycerol Chemical compound [O-][N+](=O)OC(CO)CO[N+]([O-])=O GFVHBTOOPNJKLV-UHFFFAOYSA-N 0.000 claims 2
- HXWLJBVVXXBZCM-UHFFFAOYSA-N 2,3-dihydroxypropyl nitrate Chemical compound OCC(O)CO[N+]([O-])=O HXWLJBVVXXBZCM-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 claims 2
- 229960001747 cinchocaine Drugs 0.000 claims 2
- UQXKXGWGFRWILX-UHFFFAOYSA-N ethylene glycol dinitrate Chemical compound O=N(=O)OCCON(=O)=O UQXKXGWGFRWILX-UHFFFAOYSA-N 0.000 claims 2
- 150000002430 hydrocarbons Chemical class 0.000 claims 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
- 229960000890 hydrocortisone Drugs 0.000 claims 2
- GAPFWGOSHOCNBM-UHFFFAOYSA-N isopropyl nitrate Chemical compound CC(C)O[N+]([O-])=O GAPFWGOSHOCNBM-UHFFFAOYSA-N 0.000 claims 2
- 229960000201 isosorbide dinitrate Drugs 0.000 claims 2
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- RDLIBIDNLZPAQD-UHFFFAOYSA-N 1,2,4-butanetriol trinitrate Chemical compound [O-][N+](=O)OCCC(O[N+]([O-])=O)CO[N+]([O-])=O RDLIBIDNLZPAQD-UHFFFAOYSA-N 0.000 claims 1
- ASIGVDLTBLZXNC-UHFFFAOYSA-N 1,3-dinitroglycerol Chemical compound [O-][N+](=O)OCC(O)CO[N+]([O-])=O ASIGVDLTBLZXNC-UHFFFAOYSA-N 0.000 claims 1
- 239000005662 Paraffin oil Substances 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 244000309464 bull Species 0.000 claims 1
- 229960003827 isosorbide mononitrate Drugs 0.000 claims 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 claims 1
- 239000002480 mineral oil Substances 0.000 claims 1
- 235000010446 mineral oil Nutrition 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Steroid Compounds (AREA)
Claims (36)
1. Pharmazeutische Zusammensetzung, die für die topische Behandlung einer
Analerkrankung brauchbar ist, umfassend einen organischen Stickoxid-Donor in Kombination mit einem Trägerin einer Form, die ausgewählt ist
aus der Gruppe, die besteht aus einem Pulver, einem Aerosol, einer
Flüssigkeit, einschließlich einer eingedickten Flüssigkeit, einer Salbe und einem Suppositorium; wobei, wenn es sich bei dem organischen Stickoxid-Donor
um lediglich Nitroglycerin handelt und die Zusammensetzung eine &iacgr;&ogr; Salbe auf der Basis von Weichparaffin oder Mineralöl ist, das Nitroglycerin
dann in einer Menge, die 2,0 Gewichts-% nicht einschließt, anwesend ist.
2. Zusammensetzung nach Anspruch 1, in welcher der organische Stickoxid-Donor
Nitroglycerin ist.
3. Zusammensetzung nach Anspruch 2, bei der es sich um eine Salbe handelt.
4. Zusammensetzung nach Anspruch 1, in welcher das Nitroglycerin der
organische Stickoxid-Donor, in einer Menge von etwa 0,25 bis etwa 0,45 Gewichts-% vorliegend, in einer Salbe ist.
5. Zusammensetzung nach Anspruch 1, in welcher Nitroglycerin der organische Stickoxid-Donor, in einer Menge von etwa 0,07 bis etwa 0,15
Gewichts-% vorliegend, in einer Salbe ist.
6. Zusammensetzung nach Anspruch 1, bei der es sich um ein Suppositorium
handelt.
so
7. Zusammensetzung nach Anspruch 1, in welcher der organische Stickoxid-
Donor mindestens ein durch die folgende allgemeine Formel dargestelltes
organisches Nitrat einschließt:
Ri-CR1R^O-NO2),
worin:
R, R' und R" unabhängig bei jedem Auftreten eine organische oder
worin:
R, R' und R" unabhängig bei jedem Auftreten eine organische oder
•u
&ugr; / &igr; y &ogr;
Hydro-Einheit oder eine kovalente Bindung darstellen und &khgr; eine ganze
Zahl von 1 bis etwa 12 ist.
8. Zusammensetzung nach Anspruch 7, in welcher R ein Kohlenwasserstoff
oder Sauerstoff-substituierter Kohlenwasserstoff mit 2 bis etwa 12
Kohlenstoffen ist;
R' 2 bis 6 Kohlenstoffe und 0 bis 2 Sauerstoffe aufweist, eine Hydro-Einheit
oder eine kovalente Bindung darstellt;
R" eine Hydro-Einheit ist; und
&iacgr;&ogr; &khgr; 2 bis 6 ist.
R" eine Hydro-Einheit ist; und
&iacgr;&ogr; &khgr; 2 bis 6 ist.
9. Zusammensetzung nach Anspruch 8, die Nitroglycerin; Ethylenglycoldinitrat;
Isopropylnitrat; Glyceryl-1-mononitrat; Glyceryl-l,2-dinitrat;
Glyceryl-l,3-dinitrat; Butan-l,2,4-triol-trinitrat; Erythrityltetranitrat;
Pentaerythrityltetranitrat; Isosorbitmononitrat; und Isosorbitdinitrat ausschließt.
10. Zusammensetzung nach Anspruch 1 in Form einer Salbe oder eines
Suppositoriums, in welcher der organische Stickoxid-Donor mindestens
&ogr; ein organisches Nitrat einschließt, das ausgewählt ist aus der Gruppe, die
aus Ethylenglycoldinitrat; Isopropylnitrat; Glyceryl-1-mononitrat; Glyceryl-1,2-dinitrat;
Glyceryl-l,3-dinitrat; Butan-l,2,4-triol-trinitrat; Erythrityltetranitrat;
Pentaerythrityltetranitrat; Isosorbitmononitrat; und Isosorbitdinitrat besteht.
11. Zusammensetzung nach Anspruch 1, in welcher der organische Nitrat-Donor
ausgewählt ist aus der Gruppe, die aus einem oder mehreren von Erythrityltetranitrat; Pentaerythrityltetranitrat und Isosorbitdinitrat besteht.
12. Pharmazeutische Zusammensetzung, die für die Behandlung von Analerkrankung
brauchbar ist, umfassend einen organischen Stickoxid-Donor in Kombination mit einem Corticosteroid und einem pharmazeutisch
annehmbaren topischen Träger.
3 C / &Idigr; y "I h :■
13. Zusammensetzung nach Ansprach 12, in welcher der organische Stickoxid-Donor
Nitroglycerin ist.
14. Zusammensetzung nach Ansprach 13, in welcher das Corticosteroid
Hydrocortison ist.
15. Zusammensetzung nach Ansprach 12, in welcher auch ein topisches
Anästhetikum anwesend ist.
16. Pharmazeutische Zusammensetzung, die für die Behandlung von Analerkrankung
brauchbar ist, umfassend einen organischen Stickoxid-Donor in Kombination mit einem topischen Anästhetikum und einem Träger.
17. Zusammensetzung nach Ansprach 16, in welcher es sich beim organischen
Stickoxid-Donor um Nitroglycerin handelt.
18. Zusammensetzung nach Ansprach 17, in welcher das topische Anästhetikum
Dibucain ist.
19. Verfahren zur Behandlung einer Analerkrankung, umfassend die Kontaktierang des geeigneten Analbereiches mit einer effektiven Menge
Stickoxid.
20. Verfahren nach Ansprach 19, in welchem das Stickoxid durch Freisetzung
aus einem organischen Stickoxid-Donor bereitgestellt wird.
21. Verfahren nach Ansprach 20, in welchem der organische Stickoxid-Donor
ein durch die folgende allgemeine Formel dargestelltes organisches Nitrat ist:
0 R(-CR'R"-O-NO2)A
worin:
R, R' und R" unabhängig bei jedem Auftreten eine organische oder Hydro-Einheit oder eine kovalente Bindung darstellen und &khgr; eine ganze
Zahl von 1 bis etwa 12 ist.
G 7 &igr; &ngr; -, t "
22. Verfahren nach Anspruch 21, in welchem R ein Kohlenwasserstoff oder
Sauerstoff-substituierter Kohlenwasserstoff mit 2 bis etwa 12 Kohlenstoffen
ist; _
R' 2 bis 6 Kohlenstoffe und 0 bis 2 Sauerstoffe aufweist, eine Hydro-Einheit
oder eine kovalente Bindung darstellt;
R" eine Hydro-Einheit ist; und
&khgr; 2 bis 6 ist.
&khgr; 2 bis 6 ist.
23. Verfahren nach Anspruch 20, in welchem der organische Stickoxid-Donor
&iacgr;&ogr; Nitroglycerin ist.
24. Verfahren nach Anspruch 20, in welchem mindestens ein aus der Gruppe,
die aus einem Corticosteroid und einem topischen Anästhetikum besteht, ausgewähltes Mittel in Verbindung mit dem Stickoxid-Donor eingesetzt
wird.
25. Verfahren nach Anspruch 21, in welchem mindestens ein aus der Gruppe,
die aus einem Corticosteroid und einem topischen Anästhetikum besteht, ausgewähltes Mittel in Verbindung mit dem Stickoxid-Donor eingesetzt
wird.
26. Verfahren nach Anspruch 25, in welchem das Corticosteroid Hydrocortison
ist und das topische Anästhetikum Dibucain ist.
27. Verfahren nach Anspruch 19, durch welches Analschmerz unter Kontrolle
gehalten wird.
28. Verfahren nach Anspruch 19, in welchem die Analerkrankung eine
Analfissur oder ein Analgeschwür ist.
29. Verfahren nach Anspruch 19, in welchem die Analerkrankung eine
Hämorrhoiden-Erkrankung ist.
30. Verfahren nach Anspruch 19, in welchem die Analerkrankung ein Levatorkrampf ist.
5 G / s ^ &idigr; &zgr; ."■:
31. Verfahren nach Anspruch 28, in welchem Nitroglycerin eingesetzt wird.
32. Verfahren nach Anspruch 29, in welchem Nitroglycerin eingesetzt wird.
33. Verfahren nach Anspruch 30, in welchem Nitroglycerin eingesetzt wird.
34. Verfahren nach Anspruch 31, durch welches Analschmerz unter Kontrolle
gehalten wird.
&iacgr;&ogr; 35. Verfahren nach Anspruch 32, durch welches Analschmerz unter Kontrolle
gehalten wird.
36. Verfahren nach Anspruch 33, durch welches Analschmerz unter Kontrolle
gehalten wird.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/250,555 US5504117A (en) | 1994-05-27 | 1994-05-27 | Pharmacologic preparation for the treatment of anal disorders |
US37108895A | 1995-01-10 | 1995-01-10 | |
PCT/US1995/004364 WO1995032715A1 (en) | 1994-05-27 | 1995-04-10 | Nitric oxide donor composition and method for treatment of anal disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
DE719145T1 true DE719145T1 (de) | 1997-02-13 |
Family
ID=26940977
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE0719145T Pending DE719145T1 (de) | 1994-05-27 | 1995-04-10 | Stickstoffoxyd abgebendes präparat und verfahren zur behandlung von analen erkrankungen |
DE69535607T Expired - Lifetime DE69535607T2 (de) | 1994-05-27 | 1995-04-10 | Zusammensetzung enthaltend Stickstoffoxid-donatoren und Methode zur Behandlung analer Krankheiten |
DE69518729T Revoked DE69518729T2 (de) | 1994-05-27 | 1995-04-10 | Stickstoffoxyd abgebendes präparat zur behandlung von analen erkrankungen |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69535607T Expired - Lifetime DE69535607T2 (de) | 1994-05-27 | 1995-04-10 | Zusammensetzung enthaltend Stickstoffoxid-donatoren und Methode zur Behandlung analer Krankheiten |
DE69518729T Revoked DE69518729T2 (de) | 1994-05-27 | 1995-04-10 | Stickstoffoxyd abgebendes präparat zur behandlung von analen erkrankungen |
Country Status (16)
Country | Link |
---|---|
US (4) | US5693676A (de) |
EP (2) | EP1051972B1 (de) |
JP (3) | JP3211892B2 (de) |
KR (1) | KR100386525B1 (de) |
CN (1) | CN1107499C (de) |
AT (2) | ATE374607T1 (de) |
AU (1) | AU2282395A (de) |
CA (1) | CA2168247C (de) |
DE (3) | DE719145T1 (de) |
DK (2) | DK1051972T3 (de) |
ES (2) | ES2292402T3 (de) |
GR (2) | GR960300077T1 (de) |
HK (1) | HK1032545A1 (de) |
IL (1) | IL113448A (de) |
PT (2) | PT719145E (de) |
WO (1) | WO1995032715A1 (de) |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1051972B1 (de) * | 1994-05-27 | 2007-10-03 | Strakan International Limited | Zusammensetzung enthaltend Stickstoffoxid-donatoren und Methode zur Behandlung analer Krankheiten |
US20050137191A1 (en) * | 1996-06-04 | 2005-06-23 | Thatcher Gregory R. | Nitrate esters and their use for mitigating cellular damage |
US7115661B1 (en) * | 1999-12-29 | 2006-10-03 | Queen's University At Kingston | Methods and compositions for mitigating pain |
AU733047C (en) | 1997-02-24 | 2002-05-16 | S.L.A. Pharma Ag | Pharmaceutical composition |
US8048875B1 (en) | 1997-02-24 | 2011-11-01 | S.L.A. Pharma Ag | Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker |
ID20270A (id) * | 1997-05-18 | 1998-11-19 | Adel Abdel Wadood Gomaa Prof D | Preparat topikal yang baru untuk pengobatan ketidak-fungsian penis |
US6159944A (en) * | 1998-02-27 | 2000-12-12 | Synchroneuron, Llc | Method for treating painful conditions of the anal region and compositions therefor |
EP1143956A3 (de) * | 1998-12-14 | 2001-12-12 | Cellegy Pharmaceuticals, Inc | Zusammensetzungen und verfahren zur behandlung von anorektalen krankheiten |
US6627632B2 (en) | 1998-12-14 | 2003-09-30 | Cellegy Pharmaceuticals, Inc. | Compositions and methods for the treatment of anorectal disorders |
US6391869B1 (en) * | 1998-12-14 | 2002-05-21 | Cellergy Pharmaceuticals, Inc. | Compositions and methods for the treatment of anorectal disorders |
US6077227A (en) * | 1998-12-28 | 2000-06-20 | Medtronic, Inc. | Method for manufacture and implant of an implantable blood vessel cuff |
ES2151454B1 (es) * | 1999-05-06 | 2001-07-01 | Szlec Christopher Dura | Pomada para el tratamiento de la fisura anal cronica y otros procesos inflamatorios del ano. |
DE19945484A1 (de) * | 1999-09-22 | 2001-04-05 | Kolb Bachofen Victoria | NO-freisetzende topisch applizierbare Zusammensetzung |
AU2727701A (en) * | 1999-12-15 | 2001-06-25 | Cellegy Pharmaceuticals, Inc. | Nitroglycerin ointment for treatment of pain associated with anal disease |
WO2001054679A2 (en) * | 2000-01-27 | 2001-08-02 | Children's Hospital Research Foundation | Transdermal composition containing an anesthetic and a vasodilator agent |
AUPQ577700A0 (en) * | 2000-02-22 | 2000-03-16 | K. King & Co Pty Limited | Method of treatment of anorectal disorders |
HUP0002628A2 (en) * | 2000-07-14 | 2002-06-29 | Keri Pharma Kft | Pharmaceutical combinations for treating diabetes |
BRPI0113085B1 (pt) * | 2000-08-11 | 2017-09-19 | R. Whitlock David | Preparation to be applied to a surface of an individual understanding ammonia oxidizing bacteria that metabolize transparation, and clothing article |
ATE450187T1 (de) * | 2001-12-06 | 2009-12-15 | Univ Duke | Verhinderung von hautlappennekrose in der plastischen chirurgie |
US6833139B1 (en) | 2002-01-09 | 2004-12-21 | Ferndale Laboratories, Inc. | Composition and method for the treatment of anorectal disorders |
AU2003222569A1 (en) * | 2002-01-11 | 2003-07-24 | Whitlock, David R. | Compositions including ammonia oxidizing bacteria and methods of using same |
US20040018237A1 (en) * | 2002-05-31 | 2004-01-29 | Perricone Nicholas V. | Topical drug delivery using phosphatidylcholine |
US20060078580A1 (en) | 2004-10-08 | 2006-04-13 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
US7740875B2 (en) * | 2004-10-08 | 2010-06-22 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
US20060105027A1 (en) * | 2004-11-17 | 2006-05-18 | Lindsey Berkson | Method for treating skin ulcers |
EP1827466A4 (de) * | 2004-11-17 | 2009-11-11 | Lindsey Berkson | Zusammensetzung und verfahren zur erleichterung der heilung von nicht heilenden und langsam heilenden wunden und geschwüren |
US7731993B2 (en) * | 2004-11-17 | 2010-06-08 | Lindsey Berkson | Composition for treating a dermal anomaly |
WO2006085127A1 (en) * | 2005-02-08 | 2006-08-17 | Antibe Therapeutics, Inc. | Topical compositions |
WO2006084913A2 (en) * | 2005-02-11 | 2006-08-17 | Nolabs Ab | Device for treatment of rectal disorders, and manufacturing process for the same, involving nitric oxide |
CA2912259C (en) | 2005-05-27 | 2020-04-28 | Mark H. Schoenfisch | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
WO2007021900A2 (en) * | 2005-08-10 | 2007-02-22 | Cutler Robert S | Compositions and methods for treating wounds |
US7507842B2 (en) | 2005-08-12 | 2009-03-24 | Radiorx, Inc. | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof |
US20070135380A1 (en) * | 2005-08-12 | 2007-06-14 | Radiorx, Inc. | O-nitro compounds, pharmaceutical compositions thereof and uses thereof |
AU2012203798B2 (en) * | 2005-08-12 | 2013-11-07 | Northrop Grumman Systems Corporation | O-nitro compounds, pharmaceutical compositons thereof and uses thereof |
CN103263668A (zh) * | 2006-03-09 | 2013-08-28 | 萨利克斯药品公司 | 利福昔明抗直肠功能障碍制剂 |
US20080193385A1 (en) * | 2007-02-08 | 2008-08-14 | Todd Maibach | Compositions and methods for treating neuropathy |
JP2011525116A (ja) * | 2008-06-24 | 2011-09-15 | マイクロファーマ・リミテッド | 一酸化窒素デバイス、ならびに創傷の治癒、皮膚障害および微生物感染症の治療の方法 |
US11684624B2 (en) | 2009-06-24 | 2023-06-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9526738B2 (en) | 2009-08-21 | 2016-12-27 | Novan, Inc. | Topical gels and methods of using the same |
US9919072B2 (en) | 2009-08-21 | 2018-03-20 | Novan, Inc. | Wound dressings, methods of using the same and methods of forming the same |
US9023890B2 (en) * | 2009-12-02 | 2015-05-05 | The Charlotte-Mecklenburg Hospital Authority | Nitrate esters and their use for the treatment of muscle and muscle related diseases |
US8471041B2 (en) | 2010-02-09 | 2013-06-25 | Alliant Techsystems Inc. | Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same |
US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
PT2658551T (pt) | 2010-12-29 | 2020-07-24 | Strategic Science & Tech Llc | Tratamento da disfunção erétil e outras indicações |
WO2012118819A2 (en) | 2011-02-28 | 2012-09-07 | Novan, Inc. | Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same |
EP2685962A1 (de) | 2011-03-17 | 2014-01-22 | Transdermal Biotechnology, Inc. | Topische stickoxidsysteme sowie verfahren zu ihrer verwendung |
US9452117B2 (en) | 2011-06-01 | 2016-09-27 | The Charlotte-Mecklenburg Hospital Authority | Nitrate esters and their use for the treatment of muscle and muscle related diseases |
US8664247B2 (en) | 2011-08-26 | 2014-03-04 | Radiorx, Inc. | Acyclic organonitro compounds for use in treating cancer |
JP6019126B2 (ja) | 2011-10-07 | 2016-11-02 | エピセントアーレックス・インコーポレイテッドEpicentRx, Inc. | 有機ニトロチオエーテル化合物およびその医療用途 |
US20140308260A1 (en) | 2011-10-07 | 2014-10-16 | Radiorx, Inc. | Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products |
DE102012009570A1 (de) * | 2012-05-09 | 2013-11-14 | Naum Goldstein | Komposition für nasale Anwendung |
US8871259B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Techniques and systems for treatment of neuropathic pain and other indications |
US8871260B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and compositions for muscular and neuromuscular diseases |
US8871261B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Cancer treatments and compositions for use thereof |
US8871262B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Compositions and methods for treatment of osteoporosis and other indications |
US8871256B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and systems for treatment of inflammatory diseases with nitric oxide |
US8871258B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment and prevention of learning and memory disorders |
US8871255B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment of skin and soft tissue infection with nitric oxide |
US8871257B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery |
US8871254B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system |
US9314423B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Hair treatment systems and methods using peptides and other compositions |
US9314422B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
US9849160B2 (en) | 2013-03-13 | 2017-12-26 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
US9314417B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US9295637B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Compositions and methods for affecting mood states |
US9241899B2 (en) | 2013-03-13 | 2016-01-26 | Transdermal Biotechnology, Inc. | Topical systems and methods for treating sexual dysfunction |
US9724419B2 (en) | 2013-03-13 | 2017-08-08 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
US20140271937A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
US9393265B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US9295636B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US9320758B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
US20140271938A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
US9393264B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
US20140271731A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
US9750787B2 (en) | 2013-03-13 | 2017-09-05 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
US9687520B2 (en) | 2013-03-13 | 2017-06-27 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
US9295647B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
US9339457B2 (en) | 2013-03-13 | 2016-05-17 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
US9314433B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
US9387159B2 (en) | 2013-03-13 | 2016-07-12 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US9320706B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
EP2968124A1 (de) * | 2013-03-15 | 2016-01-20 | Strategic Science & Technologies, LLC | Transdermale formulierungen von fluticason |
US11225640B2 (en) | 2014-04-15 | 2022-01-18 | Aobiome Llc | Ammonia oxidizing bacteria for treatment of psoriasis |
EP4219679A3 (de) | 2014-04-15 | 2023-08-09 | Aobiome LLC | Ammoniak-oxidierender nitrosomonas eutropha stamm d23 |
US10342778B1 (en) | 2015-10-20 | 2019-07-09 | Epicentrx, Inc. | Treatment of brain metastases using organonitro compound combination therapy |
US9987270B1 (en) | 2015-10-29 | 2018-06-05 | Epicentrix, Inc. | Treatment of gliomas using organonitro compound combination therapy |
DK3402480T3 (da) | 2016-01-11 | 2021-06-28 | Epicentrx Inc | Sammensætninger og fremgangsmåder til intravenøs administration af 2-brom-1-(3,3-dinitroazetidin-1-yl)ethanon |
BR112019007453A2 (pt) | 2016-10-14 | 2019-07-16 | Epicentrx Inc | organonitro de sulfoxialquila e compostos relacionados e composições farmacêuticas para uso em medicina |
IL271777B2 (en) | 2017-07-07 | 2024-09-01 | Epicentrx Inc | Preparations for intravenous administration of medical substances |
JP2021506958A (ja) | 2017-12-13 | 2021-02-22 | オンクォリティ ファーマシューティカルズ チャイナ エルティーディーOnquality Pharmaceuticals China Ltd. | Egfr阻害に関連する疾患を予防又は治療する方法 |
US11510901B2 (en) | 2018-01-08 | 2022-11-29 | Epicentrx, Inc. | Methods and compositions utilizing RRx-001 combination therapy for radioprotection |
CA3097067A1 (en) | 2018-04-16 | 2019-10-24 | Onquality Pharmaceuticals China Ltd. | Method for preventing or treating side effects of cancer therapy |
RU2733080C1 (ru) | 2019-12-13 | 2020-09-29 | Александр Евгеньевич Баранников | Фармакологическая композиция для лечения проктологических заболеваний (варианты). |
US12070440B2 (en) | 2022-06-27 | 2024-08-27 | Permeatus, Inc. | Topical formulations of nitroglycerin |
KR102680910B1 (ko) * | 2022-11-02 | 2024-07-03 | 이상린 | 재사용 가능한 지퍼용 체결기구 |
US12036398B1 (en) * | 2023-12-22 | 2024-07-16 | Pelvic Rehabilitation Medicine | Treatment of neuromuscular dysfunction |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE304730C (de) | ||||
US814408A (en) * | 1905-02-28 | 1906-03-06 | Frederick Albert Steele | Toilet article. |
US2840080A (en) * | 1956-12-18 | 1958-06-24 | Millard J Clark | Hygienic pad |
US3419571A (en) | 1966-04-06 | 1968-12-31 | Warner Lambert Pharmaceutical | Method for relieving coronary insufficiency |
US4118480A (en) * | 1973-02-09 | 1978-10-03 | Charles V. Stoelker | Pharmaceutical preparation for treating hemorrhoids and anal fissures |
GB1548022A (en) * | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
ZA771135B (en) * | 1977-02-25 | 1978-05-30 | J Prinsloo | Mediese preparaat |
JPS5562012A (en) * | 1978-11-06 | 1980-05-10 | Teijin Ltd | Slow-releasing preparation |
US4842854A (en) * | 1979-05-29 | 1989-06-27 | Vsesojuzny Kardiologichesky Nauchny Tsentr Akademii Meditsinskiki Nauk Ssr | Antianginal plate for treating ischemic heart disease |
US4226849A (en) * | 1979-06-14 | 1980-10-07 | Forest Laboratories Inc. | Sustained release therapeutic compositions |
CA1163561A (en) * | 1979-11-06 | 1984-03-13 | Cyril Boroda | Preparation containing nitroglycerine and optionally other medicaments and preparation thereof |
US4657906A (en) | 1982-06-05 | 1987-04-14 | Smith Kline & French Laboratories Ltd. | Heterocyclic compounds having inotropic activity |
US4608249A (en) | 1982-11-02 | 1986-08-26 | Nitto Electric Industrial Co., Ltd. | Hydrophilic therapeutic material |
US4514384A (en) * | 1983-03-14 | 1985-04-30 | Gallina Damian J | Hemorrhoid treatment method |
JPS59184135A (ja) | 1983-04-04 | 1984-10-19 | Teijin Ltd | グリセリンピログルタミン酸エステル類を含有する医薬品組成物 |
JPS6267017A (ja) | 1985-09-19 | 1987-03-26 | Sanwa Kagaku Kenkyusho:Kk | 被膜形成型揮散性薬物含有軟膏剤 |
US4683242A (en) | 1985-10-28 | 1987-07-28 | A. H. Robins Company, Incorporated | Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters |
US4764381A (en) | 1985-12-06 | 1988-08-16 | Key Pharmaceuticals, Inc. | Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol |
HU199678B (en) * | 1988-07-08 | 1990-03-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing aerosols containing nitroglicerol |
US5183663A (en) * | 1989-06-07 | 1993-02-02 | Hercules Incorporated | Treating skin lesions |
US5059603A (en) * | 1989-06-12 | 1991-10-22 | Centuries Laboratories, Inc. | Method and composition for treating impotence |
US5085650A (en) * | 1989-10-20 | 1992-02-04 | Giglio Frank A | Gynecological urethral suppository |
JPH0692317B2 (ja) | 1990-08-06 | 1994-11-16 | 龍也 橋岡 | 肛門用外用薬剤 |
DE4038203A1 (de) | 1990-11-30 | 1992-06-04 | Kali Chemie Pharma Gmbh | Pharmazeutische spray-zubereitungen mit coronaraktiven wirkstoffen |
US5508045A (en) | 1992-10-09 | 1996-04-16 | The Regents Of The University Of California | Method and agents for control and management of labor during pregnancy |
US5439938A (en) * | 1993-04-07 | 1995-08-08 | The Johns Hopkins University | Treatments for male sexual dysfunction |
US5595970A (en) * | 1993-07-16 | 1997-01-21 | Schering Aktiengesellschaft | Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors |
AUPM424794A0 (en) | 1994-03-04 | 1994-03-31 | Koren Laboratories Pty Ltd | Treatment of anorectal disorders |
WO1995006466A1 (en) * | 1993-09-01 | 1995-03-09 | Koren Laboratories Pty. Limited | Treatment of anorectal disorders |
AU708694C (en) | 1993-09-01 | 2002-12-19 | Cellegy Australia Pty Ltd | Treatment of anorectal disorders |
US5504117A (en) * | 1994-05-27 | 1996-04-02 | Neptune Pharmaceutical Corporation | Pharmacologic preparation for the treatment of anal disorders |
EP1051972B1 (de) * | 1994-05-27 | 2007-10-03 | Strakan International Limited | Zusammensetzung enthaltend Stickstoffoxid-donatoren und Methode zur Behandlung analer Krankheiten |
US5595753A (en) * | 1995-04-14 | 1997-01-21 | President And Fellows Of Harvard College | Topical formulations and methods for treating hemorrhoidal pain and sphincter and smooth muscle spasm in the gastrointestinal tract |
US5827889A (en) * | 1996-04-23 | 1998-10-27 | Robert Cunico | Anal fissure treatment preparation and method |
AU733047C (en) | 1997-02-24 | 2002-05-16 | S.L.A. Pharma Ag | Pharmaceutical composition |
IT1297886B1 (it) | 1997-02-28 | 1999-12-20 | Carmine Antropoli | Nifedipina per uso topico |
-
1995
- 1995-04-10 EP EP00202372A patent/EP1051972B1/de not_active Expired - Lifetime
- 1995-04-10 PT PT95916264T patent/PT719145E/pt unknown
- 1995-04-10 DE DE0719145T patent/DE719145T1/de active Pending
- 1995-04-10 ES ES00202372T patent/ES2292402T3/es not_active Expired - Lifetime
- 1995-04-10 AU AU22823/95A patent/AU2282395A/en not_active Abandoned
- 1995-04-10 WO PCT/US1995/004364 patent/WO1995032715A1/en active IP Right Grant
- 1995-04-10 CA CA002168247A patent/CA2168247C/en not_active Expired - Lifetime
- 1995-04-10 JP JP50083596A patent/JP3211892B2/ja not_active Expired - Lifetime
- 1995-04-10 ES ES95916264T patent/ES2092460T3/es not_active Expired - Lifetime
- 1995-04-10 CN CN95190687A patent/CN1107499C/zh not_active Expired - Lifetime
- 1995-04-10 DE DE69535607T patent/DE69535607T2/de not_active Expired - Lifetime
- 1995-04-10 EP EP95916264A patent/EP0719145B1/de not_active Revoked
- 1995-04-10 PT PT00202372T patent/PT1051972E/pt unknown
- 1995-04-10 KR KR1019960700442A patent/KR100386525B1/ko not_active IP Right Cessation
- 1995-04-10 AT AT00202372T patent/ATE374607T1/de active
- 1995-04-10 DE DE69518729T patent/DE69518729T2/de not_active Revoked
- 1995-04-10 DK DK00202372T patent/DK1051972T3/da active
- 1995-04-10 DK DK95916264T patent/DK0719145T3/da active
- 1995-04-10 AT AT95916264T patent/ATE196082T1/de not_active IP Right Cessation
- 1995-04-20 IL IL11344895A patent/IL113448A/xx not_active IP Right Cessation
-
1996
- 1996-06-20 US US08/666,264 patent/US5693676A/en not_active Expired - Lifetime
-
1997
- 1997-01-31 GR GR960300077T patent/GR960300077T1/el unknown
-
2000
- 2000-06-07 JP JP2000171337A patent/JP3866906B2/ja not_active Expired - Fee Related
- 2000-12-06 GR GR20000402692T patent/GR3035001T3/el not_active IP Right Cessation
-
2001
- 2001-03-19 US US09/812,277 patent/US20010025057A1/en not_active Abandoned
- 2001-05-14 HK HK01103333A patent/HK1032545A1/xx not_active IP Right Cessation
- 2001-12-11 US US10/021,168 patent/US20020161042A1/en not_active Abandoned
-
2002
- 2002-08-23 JP JP2002243611A patent/JP2003073302A/ja not_active Withdrawn
-
2003
- 2003-09-22 US US10/669,099 patent/US7189761B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE719145T1 (de) | Stickstoffoxyd abgebendes präparat und verfahren zur behandlung von analen erkrankungen | |
DE69716461T2 (de) | Antithrombotische organische nitrate | |
DE69618600T2 (de) | Colchicine derivate, deren verwendung und sie enthaltende formulierungen | |
DE19540475A1 (de) | Chirale Methylphenyloxazolidinone | |
BE901545A (fr) | Nouveaux derives de la furo-(3,4-c)-pyridine substitues en position 6, un procede pour leur preparation et compositions therapeutiques a base de ces derives. | |
CH636606A5 (de) | Verfahren zur herstellung neuer prostensaeuren und -alkylestern. | |
DE2622123A1 (de) | Prostaglandin-analoge | |
CH618968A5 (de) | ||
DE2627671A1 (de) | Arzneimittel, enthaltend ein lacton eines prostaglandins oder prostaglandinanalogen | |
EP0656889B1 (de) | 9-chlor-prostaglandin-ester und -amide und ihre verwendung für die herstellung von arzneimitteln | |
DE2719246C2 (de) | Dimaleat von 1[2(4-Methoxybenzhydryloxyäthyl)]-4-[3(4-fluorbenzoyl)-propyl]-piperazin, Verfahren zu dessen Herstellung und diese Verbindung enthaltendes Arzneimittel | |
DE1518241B1 (de) | Neue alpha-Phenoxyalkylcarbonsaeurepolyolester und Verfahren zu ihrer Herstellung | |
DE69017839T2 (de) | NMDA-blockierende Verbindungen, pharmazeutische Präparate, deren Herstellung und Verwendung. | |
WO1990009373A1 (de) | Hydroxyalkancarbonsäure-derivate, deren herstellung und verwendung | |
DE2106768B2 (de) | Komplexverbindungen aus Organonatriumverbindungen und Chelate bildenden Polyaminen, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Telomerisationskatalysatoren und zur Reinigung von Organonatriumverbindungen | |
DE3880561T2 (de) | Actinoninderivate mit physiologischen Aktivitäten. | |
DD243277A5 (de) | Verfahren zur herstellung neuer 3-phenyl-2-propenamin-derivate | |
DE2910474C2 (de) | ||
DE2632118A1 (de) | Apovincaminolester und verfahren zu deren herstellung | |
DE223671T1 (de) | Arzneimittel mit synergistischer entzuendungshemmender wirkung auf der basis eines corticosteroiden und eines beta-agonisten. | |
CH640847A5 (en) | Process for preparing analogues of 5,6-dihydroprostacyclin | |
DE1793462C3 (de) | N-Aryl-anthranilsäureester monosubstituierter gem-Diole, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate | |
DE2542096C2 (de) | Symmetrische Dihydroxydithiahexadecane, Verfahren zuihrer Herstellung und diese enthaltende Heilmittel | |
DE3325677C2 (de) | ||
DE858401C (de) | Verfahren zur Herstellung von Nicotinsaeureestern |